These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 23925444)

  • 1. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.
    Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JC; Wang CQ; Welsh B; Nijsten T; Murrell DF
    JAMA Dermatol; 2013 Oct; 149(10):1186-91. PubMed ID: 23925444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.
    Tjokrowidjaja A; Daniel BS; Frew JW; Sebaratnam DF; Hanna AM; Chee S; Dermawan A; Wang CQ; Lim C; Venugopal SS; Rhodes LM; Welsh B; Nijsten T; Murrell DF
    Br J Dermatol; 2013 Nov; 169(5):1000-6. PubMed ID: 24102329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires.
    Kalinska-Bienias A; Jakubowska B; Kowalewski C; Murrell DF; Wozniak K
    Adv Med Sci; 2017 Mar; 62(1):92-96. PubMed ID: 28208086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaire.
    Yang B; Chen G; Yang Q; Yan X; Zhang Z; Murrell DF; Zhang F
    Health Qual Life Outcomes; 2017 Feb; 15(1):31. PubMed ID: 28153023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires.
    Saleh MA; Zaraa I; Doss N; Saleh NA; Murrell DF
    An Bras Dermatol; 2019; 94(4):399-404. PubMed ID: 31644610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA.
    Sebaratnam DF; Okawa J; Payne A; Murrell DF; Werth VP
    Qual Life Res; 2015 Sep; 24(9):2257-60. PubMed ID: 25795375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese version of the treatment of autoimmune bullous disease quality of life questionnaire: Reliability and validity.
    Chen G; Yang B; Zhang Z; Yang Q; Yan X; Murrell DF; Zhang F
    Indian J Dermatol Venereol Leprol; 2018; 84(4):431-436. PubMed ID: 28485307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome measures for autoimmune blistering diseases.
    Zhao CY; Murrell DF
    J Dermatol; 2015 Jan; 42(1):31-6. PubMed ID: 25558950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of autoimmune blistering diseases on work productivity.
    Wang EQ; Radjenovic M; Castrillón MA; Feng GHY; Murrell DF
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1959-1966. PubMed ID: 29730897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.
    Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP
    Front Immunol; 2019; 10():2571. PubMed ID: 31781098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris.
    Teimourpour A; Hedayat K; Salarvand F; Ghandi N; Ghiasi M; Mahmoudi H; Balighi K; Toosi R; Mohebi F; Nili A; Daneshpazhooh M; Murrell DF; Chams-Davatchi C
    Int J Womens Dermatol; 2020 Sep; 6(4):306-310. PubMed ID: 33015292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Work Productivity and Quality of Life in Patients With Autoimmune Bullous Dermatoses.
    Heelan K; Hitzig SL; Knowles S; Drucker AM; Mittmann N; Walsh S; Shear NH
    J Cutan Med Surg; 2015; 19(6):546-54. PubMed ID: 25888597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing the Vascular Quality of Life Questionnaire: a new disease-specific quality of life measure for use in lower limb ischemia.
    Morgan MB; Crayford T; Murrin B; Fraser SC
    J Vasc Surg; 2001 Apr; 33(4):679-87. PubMed ID: 11296317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin-Related Quality of Life During Autoimmune Bullous Disease Course.
    Hopkins ZH; Jimenez A; Taliercio VL; Clarke JT; Hansen CB; Hull CM; Rhoads JLW; Zone JJ; Sahni VN; Kean J; Secrest AM
    JAMA Dermatol; 2023 Nov; 159(11):1185-1194. PubMed ID: 37703003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objective scoring systems for disease activity in autoimmune bullous disease.
    Sebaratnam DF; Murrell DF
    Dermatol Clin; 2011 Jul; 29(3):515-20, xi. PubMed ID: 21605820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Stroke Specific Quality of Life Scale (SS-QOL): test of reliability and validity of the Danish version (SS-QOL-DK).
    Muus I; Williams LS; Ringsberg KC
    Clin Rehabil; 2007 Jul; 21(7):620-7. PubMed ID: 17702704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.
    Rahbar Z; Daneshpazhooh M; Mirshams-Shahshahani M; Esmaili N; Heidari K; Aghazadeh N; Hejazi P; Ghajarzadeh M; Chams-Davatchi C
    JAMA Dermatol; 2014 Mar; 150(3):266-72. PubMed ID: 24429657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?
    Wijayanti A; Zhao CY; Boettiger D; Chiang YZ; Ishii N; Hashimoto T; Murrell DF
    Acta Derm Venereol; 2017 Jan; 97(1):24-31. PubMed ID: 27244117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument.
    Frew JW; Martin LK; Nijsten T; Murrell DF
    Br J Dermatol; 2009 Dec; 161(6):1323-30. PubMed ID: 19681875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease.
    Basra MK; Sue-Ho R; Finlay AY
    Br J Dermatol; 2007 Mar; 156(3):528-38. PubMed ID: 17300244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.